Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
Cutaneous type IV hypersensitivity reaction following tebentafusp treatment for uveal melanoma
Dermatol Online J. 2023 Dec 15;29(6). doi: 10.5070/D329662993.ABSTRACTTebentafusp is a bispecific protein that recently underwent FDA approval for the treatment of metastatic uveal melanoma that functions by redirecting cytotoxic T cells to glycoprotein-100, a protein highly expressed in melanoma. Although clinical trials have demonstrated that rashes are common in the first few days of treatment, little is known about skin reactions that develop later in the treatment course. Herein, we describe a type IV hypersensitivity reaction and vitiligo-like depigmentation that developed six weeks into treatment and discuss the pos...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Lauren M Fahmy Celine M Schreidah Diana E McDonnell Richard D Carvajal Cynthia M Magro Larisa J Geskin Source Type: research
